Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Eli Lilly’

Lilly gets second shot at application for ‘blockbuster’ arthritis drug

Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times for its rheumatoid arthritis drug, baricitinib. The FDA rejected the drug and asked Lilly for more data, after it pointed out instances of blood clotting in trial data.  

Bron: Pharmafile Meer lezen »

Lilly migraine treatment meets main goal in late-stage studies

Eli Lilly and Co said on Friday its experimental treatment met the main goal of reducing the number of monthly migraine headache days compared to a placebo in three late-stage studies. About 40 million Americans suffer from migraines, and the disease costs the United States about $36 billion annually in healthcare and lost productivity, according to […]

Bron: Reuters Meer lezen »

Eli Lilly’s profit beats on demand for new drugs

Eli Lilly and Co reported a bigger-than-expected quarterly adjusted profit as sales of its newest products, including a diabetes injection, more than doubled. The company provided no new information on how long U.S. regulators might delay approval of its closely watched rheumatoid arthritis drug after its surprise rejection by the Food and Drug Administration this month.

Bron: Reuters Meer lezen »

Eli Lilly updates Trulicity label to include use in combo with basal insulin

Eli Lilly and Company announced that it’s label for once ─ weekly Trulicity (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes.

Bron: Pharma Biz Meer lezen »

Lilly brings migraine drug home with $960m acquisition

Eli Lilly has announced it is to shell out $960 million to snatch up CoLucid Pharmaceuticals and specifically its migraine treatment lasmiditan; Lilly will be reclaiming the drug after it licensed it to CoLucid following its discovery in 2005.  

Bron: InPharm.com Meer lezen »

AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer’s disease

AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD).

Bron: World Pharma News Meer lezen »

AZ and Lilly come together to battle Alzheimer’s

Pharma titans Eli Lilly and AstraZeneca have announced they are to join forces to co-develop a potential Alzheimer’s treatment, currently in Phase 1 trials.  

Bron: InPharm.com Meer lezen »

Lilly Alzheimer’s drug fails to slow memory loss in big study

Eli Lilly and Co experimental drug solanezumab failed to slow loss of cognitive ability in patients with mild Alzheimer’s disease in a large trial, a major setback for the U.S. drugmaker and millions of people with the memory-robbing disease.

Bron: Reuters Meer lezen »

FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca

AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track designation for the treatment of Alzheimer’s disease.  

Bron: InPharm.com Meer lezen »

Interim analysis fails to show benefits for Lilly’s abemaciclib in advanced breast cancer

Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to continue the study without modification, despite the interim efficacy criteria not being met for trial candidate abemaciclib, plus fulvestrant, in locally advanced or metastatic breast cancer.

Bron: InPharm.com Meer lezen »

« Oudere artikelen |